We recognise the importance of Ozempic for patients living with diabetes and addressing the shortage is a top priority.
Like many other countries, there is an increased demand for this drug in Canada. Health Canada has been working with Novo Nordisk and other stakeholders since 2022 to help ensure patients get the medicine they need.
Novo Nordisk has advised Health Canada that the intermittent shortage of Ozempic that had been reported to end in October 2023 is now expected to last longer. Novo Nordisk expects intermittent shortages of the Ozempic 1 mg pen will last until March 31, 2024. It is also reporting intermittent shortages of their lower-dose pen (0.25/0.5 mg) until March 31, 2024. This is due to increased worldwide demand for the products and overall supply constraints.
Novo Nordisk will continue to receive shipments for the remainder of 2023 and into 2024. However, patients may experience intermittent delays in obtaining Ozempic during this time.
Novo Nordisk is advising stakeholders across the supply chain, including distributors, health care professionals and patient associations, of the upcoming intermittent shortages.
Novo Nordisk is encouraging pharmacists to continue to limit refill prescriptions to a 30-day supply. Patients should contact their pharmacy well in advance of running out of their current supply.
Health Canada and Novo Nordisk are closely monitoring the supply of all formats, including oral semaglutide (Rybelsus). Patients are encouraged to consult with a health care practitioner on available options.
Together with our partners, Health Canada is looking at ways to conserve existing supply, expedite resupplies to pharmacies and access foreign-authorized supply or alternatives, where possible.
We’re doing our part to ensure that patients living with diabetes can access the medication they need and rely on.
If you have questions or concerns about access to this drug, please speak to a health care professional, such as your doctor or pharmacist.